Targeting the programmed death-1/programmed death-ligand 1 axis in lymphoma

We present an overview of the clinical trials evaluating pidilizumab, nivolumab, and pembrolizumab in patients with lymphoid malignancies, and highlight some of the more promising agents in this class, currently in development. Finally, we discuss biomarkers that may predict response to therapy in patients with lymphoma across these clinical trials. Summary: A plethora of clinical trials are in progress testing immune checkpoint inhibitors in many subtypes of lymphoma, which will define their role both as a monotherapy and in combination with other biologic agents.
Source: Current Opinion in Oncology - Category: Cancer & Oncology Tags: LYMPHOMA: Edited by Bertrand Coiffier and Anne-Sophie Michallet Source Type: research